Fen-Phen and Pulmonary Hypertension Lawsuit Information The drug combination fenfluramine/phentermine, usually called Fen-Phen, is an anti-obesity treatment that utilizes two anorectics.  Fen-Phen was sold under two trade names: fenfluramine (Pondimin) and dexfenfluramine (Redux). A three-year study, published in 1992 showed that Fen-Phen was extremely effective in maintaining a significant weight loss.  However, when the patients stopped taking Fen-Phen, most regained their weight. In 1996, an article in the New England Journal of Medicine showed a statistically significant rise in primary pulmonary hypertension in patients taking Fen-Phen.  Due to these and other side effects, in late 1997, the FDA recommended that Fen-Phen no longer be prescribed. The FDA ordered fenfluramine and dexfenfluramine off the market in September 1997 after those drugs were linked to heart valve problems.  Fenfluramine is one of the ingredients in Fen-Phen, and dexfenfluramine is closely related to fenfluramine.  These drugs are manufactured by Wyeth Pharmaceuticals and American Home Products. Clearly, this drug combination used for rapid weight loss was extremely unsafe.  The manufacturers of Fen-Phen promoted this drug as safe and effective.  As shown in the study referenced above, the drug is not safe – thousands of patients taking Fen-Phen now have various cardiovascular and lung problems, such as primary pulmonary hypertension.  In addition, the drug is not effective – studies show that patients who stop taking Fen-Phen almost always regain the weight they originally lost.

• Phen Fen Lawsuit
• What is PPH?
• Diagnosing PPH
• PPH Symptoms
• Treatment of PPH
• PPH Lifestyle Changes
• Fen-Phen and PPH

• 
•